Profile data is unavailable for this security.
About the company
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote injection, for the treatment of acetaminophen poisoning; Caldolor injection, for the treatment of pain and fever, Kristalose for oral solution, a prescription laxative, for the treatment of constipation, and Omeclamox-Pak, oral, for the treatment of Helicobacter pylori infection and related duodenal ulcer disease. Its brands also include Sancuso transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia, and Vibativ injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia.
- Revenue in USD (TTM)39.55m
- Net income in USD-6.28m
- Incorporated1999
- Employees91.00
- LocationCumberland Pharmaceuticals Inc2525 W End Ave Ste 950NASHVILLE 37203-1608United StatesUSA
- Phone+1 (615) 255-0068
- Fax+1 (615) 255-0094
- Websitehttps://www.cumberlandpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Galecto Inc | 0.00 | -30.83m | 18.44m | 13.00 | -- | 0.6548 | -- | -- | -1.15 | -1.15 | 0.00 | 1.04 | 0.00 | -- | -- | 0.00 | -63.50 | -48.46 | -78.33 | -52.36 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.77 | -- | -- | -- |
| Protext Mobility Inc | 750.00 | -2.21m | 18.46m | 4.00 | -- | -- | -- | 24,615.42 | -0.4692 | -0.4692 | 0.00001 | -0.0102 | 0.0405 | -- | -- | -- | -9,400.97 | -1,587.94 | -- | -- | 86.67 | -530.19 | -232,392.00 | -17,498.83 | 0.0002 | -1.36 | -- | -- | -93.98 | -63.09 | 27.35 | -- | -- | -- |
| Raphael Pharmaceutical Inc | 0.00 | -1.28m | 18.66m | 0.00 | -- | 69.30 | -- | -- | -0.0799 | -0.0799 | 0.00 | 0.0144 | 0.00 | -- | -- | -- | -382.14 | -- | -688.47 | -- | -- | -- | -- | -- | -- | -106.00 | 0.1246 | -- | -- | -- | 61.76 | -- | -- | -- |
| KALA BIO Inc | 0.00 | -42.20m | 19.18m | 43.00 | -- | 2.50 | -- | -- | -17.94 | -17.94 | 0.00 | 2.72 | 0.00 | -- | -- | 0.00 | -59.12 | -57.83 | -77.62 | -69.32 | -- | 57.06 | -- | -1,553.61 | -- | -12.78 | 0.82 | -- | -100.00 | -- | 5.85 | -- | -17.31 | -- |
| AIM ImmunoTech Inc | 202.00k | -28.96m | 19.46m | 26.00 | -- | 2.01 | -- | 96.34 | -0.595 | -0.595 | 0.0042 | 0.2084 | 0.0068 | -- | 0.1413 | 7,769.23 | -96.75 | -45.64 | -116.18 | -48.35 | 79.21 | -231.75 | -14,337.62 | -11,695.01 | -- | -- | 0.00 | -- | 43.26 | -11.26 | -48.94 | -- | 35.73 | -- |
| Cumberland Pharmaceuticals, Inc. | 39.55m | -6.28m | 20.13m | 91.00 | -- | 0.6774 | -- | 0.509 | -0.4448 | -0.4448 | 2.75 | 2.10 | 0.4528 | 0.8383 | 3.45 | 434,643.10 | -7.25 | -7.03 | -10.66 | -9.52 | 84.66 | 79.95 | -16.01 | -17.64 | 1.11 | -25.08 | 0.3041 | -- | -5.85 | 6.15 | -12.73 | -- | -36.17 | -- |
| CERo Therapeutics Holdings Inc | 0.00 | -2.54m | 20.32m | 8.00 | -- | -- | -- | -- | -0.3796 | -0.3796 | 0.00 | -0.9226 | 0.00 | -- | -- | 0.00 | -9.96 | -- | -33.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -279.82 | -- | -- | -- |
| MEI Pharma Inc | 72.65m | 19.84m | 20.39m | 46.00 | 1.03 | 0.3427 | 1.01 | 0.2807 | 2.98 | 2.98 | 10.90 | 8.93 | 0.6425 | -- | 25.47 | 1,579,304.00 | 17.55 | -25.31 | 20.31 | -28.59 | -- | -- | 27.32 | -122.05 | -- | -- | 0.00 | -- | 19.95 | 97.56 | 41.53 | -- | -- | -- |
| Evaxion Biotech A/S - ADR | 73.00k | -22.13m | 20.39m | 49.00 | -- | -- | -- | 279.33 | -81.29 | -81.29 | 0.2665 | -1.25 | 0.0042 | -- | 0.091 | 1,489.80 | -126.74 | -100.11 | -183.85 | -131.65 | -- | -- | -30,308.22 | -131,560.30 | -- | -30.92 | 1.77 | -- | -- | -- | 4.51 | -- | 65.53 | -- |
| Alaunos Therapeutics Inc | 5.00k | -35.14m | 20.66m | 1.00 | -- | 3.28 | -- | 4,131.22 | -2.20 | -2.20 | 0.0003 | 0.3939 | 0.0001 | -- | 2.00 | 5,000.00 | -96.01 | -74.83 | -149.28 | -89.57 | -- | -- | -702,800.00 | -10,508.06 | -- | -14.83 | 0.00 | -- | -99.83 | -49.08 | 6.86 | -- | -15.56 | -- |
| Context Therapeutics Inc | 0.00 | -23.96m | 21.71m | 5.00 | -- | 1.83 | -- | -- | -1.50 | -1.50 | 0.00 | 0.7435 | 0.00 | -- | -- | 0.00 | -88.71 | -- | -102.79 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -61.53 | -- | -- | -- |
| TherapeuticsMD Inc | 1.30m | -7.70m | 21.74m | 1.00 | -- | 0.7422 | -- | 16.70 | -0.7466 | -1.00 | 0.1249 | 2.54 | 0.0195 | -- | -- | 1,302,000.00 | -11.51 | -53.35 | -19.23 | -111.61 | 100.00 | 86.67 | -591.32 | -236.57 | -- | -- | 0.00 | -- | -98.14 | -39.53 | -816.85 | -- | -- | -- |
| Sol Gel Technologies Ltd | 1.55m | -27.24m | 21.78m | 36.00 | -- | 0.5637 | -- | 14.02 | -1.02 | -1.02 | 0.0574 | 1.39 | 0.0338 | -- | 0.3774 | 43,166.67 | -59.27 | -31.60 | -64.80 | -35.49 | -- | -- | -1,752.77 | -135.76 | -- | -- | 0.00 | -- | -59.98 | 64.50 | -82.52 | -- | -33.78 | -- |
| Neurosense Therapeutics Ltd | 0.00 | -11.28m | 21.84m | 16.00 | -- | -- | -- | -- | -0.7625 | -0.7625 | 0.00 | -0.1219 | 0.00 | -- | -- | 0.00 | -207.24 | -- | -395.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 8.59 | -- | -- | -- |
Data as of May 02 2024. Currency figures normalised to Cumberland Pharmaceuticals Inc's reporting currency: US Dollar USD
14.65%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Renaissance Technologies LLCas of 31 Dec 2023 | 549.86k | 3.88% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 374.25k | 2.64% |
| Dimensional Fund Advisors LPas of 31 Dec 2023 | 365.93k | 2.58% |
| Bridgeway Capital Management LLCas of 31 Dec 2023 | 286.66k | 2.02% |
| Acadian Asset Management LLCas of 31 Dec 2023 | 188.16k | 1.33% |
| Geode Capital Management LLCas of 31 Dec 2023 | 85.27k | 0.60% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 82.40k | 0.58% |
| Newton Investment Management North America LLCas of 31 Mar 2024 | 71.84k | 0.51% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 39.79k | 0.28% |
| Two Sigma Investments LPas of 31 Dec 2023 | 33.03k | 0.23% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
